KEGG   DRUG: Mavacamten
Entry
D12265                      Drug                                   
Name
Mavacamten (JAN/USAN/INN);
Camzyos (TN)
Product
CAMZYOS (Myokardia)
Formula
C15H19N3O2
Exact mass
273.1477
Mol weight
273.3303
Structure
Class
Metabolizing enzyme substrate
 DG01642  CYP2C9 substrate
 DG01639  CYP2C19 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
ATC code: C01EB24
Product: D12265<US>
Efficacy
beta-Cardiac myosin inhibitor
  Disease
Hypertrophic cardiomyopathy [DS:H00292]
Comment
Treatment of hypertrophic cardiomyopathy
Target
MYH7 [HSA:4625] [KO:K17751]
  Pathway
hsa04022  cGMP-PKG signaling pathway
hsa04260  Cardiac muscle contraction
hsa04261  Adrenergic signaling in cardiomyocytes
hsa05410  Hypertrophic cardiomyopathy
Metabolism
Enzyme: CYP2C19 [HSA:1557]; CYP3A4 [HSA:1576], CYP2C9 [HSA:1559]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C01 CARDIAC THERAPY
   C01E OTHER CARDIAC PREPARATIONS
    C01EB Other cardiac preparations
     C01EB24 Mavacamten
      D12265  Mavacamten (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Cardiovascular Agents, Other
   Mavacamten
    D12265  Mavacamten (JAN/USAN/INN)
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   D12265  Mavacamten
  DG01639  CYP2C19 substrate
   D12265  Mavacamten
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D12265  Mavacamten
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    MYH7
     D12265  Mavacamten (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12265
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12265
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12265
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D12265
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and mutations affecting drug response
  D12265
Other DBs
CAS: 1642288-47-8
PDB-CCD: XB2[PDBj]
LinkDB
KCF data

ATOM        20
            1   C8x C     7.2800  -16.6600
            2   C8x C     7.2800  -18.0600
            3   C8x C     8.4924  -18.7600
            4   C8x C     9.7049  -18.0600
            5   C8y C     9.7049  -16.6600
            6   C8x C     8.4924  -15.9600
            7   C1c C    10.9360  -15.9490
            8   N1b N    12.1412  -16.6447
            9   C8y C    13.3235  -15.9619
            10  C8x C    14.5175  -16.6512
            11  C8y C    15.7299  -15.9512
            12  N4y N    15.7299  -14.5512
            13  C8y C    14.5360  -13.8619
            14  N4x N    13.3235  -14.5619
            15  C1c C    16.9534  -13.8446
            16  C1a C    18.1624  -14.5425
            17  C1a C    16.9532  -12.4601
            18  O5x O    14.5359  -12.4602
            19  O5x O    16.9612  -16.6622
            20  C1a C    10.9357  -14.5601
BOND        21
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 1
            13   12  13 1
            14   13  14 1
            15    9  14 1
            16   12  15 1
            17   15  16 1
            18   15  17 1
            19   13  18 2
            20   11  19 2
            21    7  20 1 #Down

» Japanese version   » Back

DBGET integrated database retrieval system